Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.34 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1341886 | 0.93 | FAAH (0.35) | FAAHMGLLSETD7 | |
| SCHEMBL1341565 | 0.93 | FAAH (0.35) | FAAHMGLLSETD7 | |
| SCHEMBL1343824 | 0.93 | FAAH (0.35) | FAAHMGLLSETD7 | |
| SCHEMBL1568443 | 0.85 | SETD7 (0.35) | TPSAB1TPSD1TPSG1SETD7 | |
| SCHEMBL1568438 | 0.85 | SETD7 (0.35) | TPSAB1TPSD1TPSG1SETD7 | |
| SCHEMBL1344593 | 0.84 | SETD7 (0.35) | SETD7 | |
| SCHEMBL1342098 | 0.84 | SETD7 (0.35) | SETD7 | |
| SCHEMBL1343297 | 0.84 | SETD7 (0.35) | SETD7 | |
| SCHEMBL1343852 | 0.82 | CHRM2 (0.37) | SETD7 | |
| SCHEMBL1343786 | 0.81 | HRH3 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2220055-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2009010429-A2 | NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | CCR5, CCR3, CCR2 | FAAH 2254/4885MGLL 3903/4885TPSAB1 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.